Structure and Toxicity of the Prefibrillar Aggregation States of Beta Peptides in Alzheimer’s Disease by Angelo Perico et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Structure and Toxicity of the Prefibrillar 
Aggregation States of Beta Peptides in 
Alzheimer’s Disease 
Angelo Perico, Denise Galante and Cristina D’Arrigo 
Institute for Macromolecular Studies (ISMAC, CNR) 
Italy 
1. Introduction 
As in several neurodegenerative diseases, Alzheimer’s disease (AD) arises when proteins 
fail to get their functional fold and aggregate in amyloid fibrils (Chiti & Dobson, 2006; Chiti 
et al., 2002). The Abeta peptides (Aβ), proteolytic products generated from beta-amyloid 
precursor protein (APP), are the subunits of amyloid fibrils that deposit in brain (Forloni et 
al., 2002; Selkoe, 1996, 2004). Aβ aggregates consist of a mixture of Aβ peptides around 40 
aminoacids having different N- and C- termini (Russo et al., 2000). It is now largely accepted 
that the pathogenic species in AD are the toxic oligomeric aggregates of Aβ that assembly in 
the brain before the formation of amyloid fibrils (Chiti & Dobson, 2006; Kirkitadze et al., 
2002; Walsh & Selkoe, 2007; Yankner & Lu, 2009). Oligomers extracted from AD brain  
potently impair synapse structure and function (Shankar et al, 2008). The structural 
characterization and neurotoxicity of these oligomeric aggregation states, even though very 
difficult to achieve due to the fast aggregation processes involved, to the heterogeneous 
peptide contents and transient organization, is of primary importance in the study of AD 
pathogenesis (Jahn et al., 2010).    
Monomeric Aβ may assume in water a β-hairpin conformation stabilized by intramolecular 
H-bonds and antiparallel β-strands  that lead to intermediate oligomeric states of Aβ 
subunits with intermolecular H-bonds and parallel β-strand organization (Campioni et al., 
2010; Ono et al., 2009; Roychaudhuri et al., 2009; Sandbergh et al., 2010). More evidence of 
the structure of oligomers and protofibrils is required that may be obtained by TEM and 
AFM (Apetri et al., 2006; Pastor et al., 2008; Yoshiike et al., 2007). Recently, new AFM 
techniques enabled to image a dynamic of Aβ oligomer formation, consistent with the 
hairpin conformation hypothesis (Mastrangelo et al., 2006). Changing the peptide 
composition of these prefibrillar aggregates, significant differences in packing strength and 
solvent exposure are eventually achieved that may be strictly related to cell toxicity.   
Between the different species of water-soluble β-peptides, found in abundance in the fibril 
brain deposits (full length Aβ1-42, Aβ1-40 and N-terminal truncated Aβs), Aβpy3-42, a 
peptide  N-terminal truncated at residue 3 (Glu) and further modified by cyclization of Glu 
to pyroglutamic acid pyGlu, (catalysed, both in vitro and in vivo, by glutamynil cyclase 
enzyme, upregulated in the cortices of AD individuals (Shilling et al., 2008)), may have an 
important role in the cooperative process leading to AD. The N termination at residue 3 in 
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Aβpy3-42 may change the attitude of the full length Aβ1-42 to aggregate gradually to a fibril 
organization, heading the β-peptide to a fast aggregation towards a relatively stable and 
toxic soluble oligomeric state.   
Recently, the faster aggregation kinetics after incubation time of the N-terminal and pyro-
modified peptides relative to the full length Aβ, were demonstrated together with significant 
morthological differences in the  pure or mixed aggregation states (D’Arrigo et al., 2009; 
Shilling et al., 2006). Demuth and coll. gave indications that prevention of formation of 
pyroglutamate-modified N-terminally truncated Aβs, such as Aβpy3-42, by inhibition of 
glutaminyl cyclase, may represent a new therapeutic strategy for alleviating amyloidoses 
(Shilling et al., 2008). In general, N-terminal pyroglutamyl modifications increase the 
aggregation propensity and also enhances resistance to degradation by proteases (Shilling et 
al., 2004, 2006). Prevention of formation of pyroglutamate-modified N-terminally truncated 
Aβs may be beneficial for AD patients. The ratio of soluble Aβ species may dictate the role of 
these aggregates on the AD amyloidosis  (He & Barrow, 1999): particularly the toxic effect of 
water-soluble Aβ  on neurons seems to be related to the predominance of Apy3-42 (Russo et 
al., 2002). This finding reinforces the idea that an adequate characterization of the oligomeric 
and prefibrillar states in terms of peptide content, structure and toxicity may be a promising 
appropriate strategy to design innovative therapies.   
The intermedium water-soluble Aβ aggregation states and their assembly process, with a 
particular attention to the role of  Apy3-42, will be the focus of the chapter.     
In section 2., a review of the efforts to characterize the structure, organization and toxicity of 
the possible prefibrillar aggregation states is given. In section 3., the hypothesis of the 
possible role in AD of the N-truncated and pyromodified A is described in comparison to 
full-length A. In section 4., the inhibition of the most toxic prefibrillar aggregation states is 
discussed as a new therapeutic strategy in AD. In section 5., concluding remarks are 
reported on the possible new molecular therapeutic strategy in AD, based on the inhibition 
of the most toxic soluble Aβ oligomeric aggregation states.  
2. Oligomeric aggregation states of beta amyloids in Alzheimer’s disease 
In this section we review recent advancements in the description and characterization of 
soluble oligomeric aggregates, their toxicity and possible role in Alzheimer pathogenesis 
(Campioni et al., 2010; Ono et al., 2009; Mastrangelo et al., 2006; Roychaudhuri et al., 2009; 
Sandbergh et al., 2010).  
Soluble oligomers, as fractionated by size exclusion chromatography, are often classified as 
low molecular weight oligomers (< 10 monomers) and high molecular weight oligomers (in 
the range of 20-40 monomers) (Mastrangelo et al., 2006; Jahn et al., 2010; Walsh et al., 1999). 
Efforts to establish rigorous structure–toxicity correlations have been hindered by the 
complex, dynamic equilibria displayed by Aβ (Ono et al., 2009; Roychaudhuri et al., 2009) . 
To clarify this matter it is therefore preliminarly necessary to choose selected well-defined, 
stabilized oligomers for establishing rigorous structure activity correlations leading to 
knowledge-based therapeutic drug design (Ono et al., 2009). The technique of photo-
induced cross-linking of unmodified proteins (PICUP) was used to stabilize oligomers of  
Aβ1-40 (Ono et al., 2009). The results are summarized quantitatively in Table1 where the 
oligomeric structure-toxicity characterization for uncross-linked, cross-linked, small 
oligomers and fibrils is reported from reference (Ono et al., 2009). 
The data suggest that monomer/dimer transition involves the largest change in the 
conformation content, from random to β-sheet conformation, as observed by circular 
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dichroism (CD); while the three dimensional change in the dimensions (TEM and AFM) of 
the oligomers has its maximum in the dimer/trimer and trimer/tetramer transitions. 
 
 
Table 1. Characteristics of A assemblies 
Finally MTT analysis (last column in Table 1, represented as the concentration in µM of a 
particular assembly that produced a level of toxicity in MTT assays that was half maximal) 
says that both cross-linked oligomeric Aβ and fibrillar Aβ were significantly more toxic than 
unassembled Aβ (dimers three-fold and tetramers 13-fold more toxic than monomers). One 
of the main results is the confirmation that monomers have very low toxicity activity while 
only when Aβ self associate, toxicity rises substantially, even though it is impossible to 
establish a degree of increasing toxicity with the number of monomers in the given oligomer  
because of the decrease in occurrence frequency of higher order oligomers. The authors 
suggest as a possible therapeutic strategy in AD to target the low order oligomers to 
unstabilize the most toxic Aβ contributing to AD neurotoxicity (Ono et al., 2009). 
Monomeric Aβ has the propensity to adopt in water solutions different conformations, 
including transient extended β-sheet conformations in the central and C-terminal regions, 
connected by turn between them, or β-hairpin (see Figure 1, panel A) (Hou et al., 2004; 
Mitternachet et al., 2010; Sandbergh et al., 2010).  
When a synthetic or purified and denatured  monomeric Aβ (say the full length peptide Aβ1-
42 or the C-terminal truncated Aβ1-40 or the N-terminal truncated Aβ3-42 and modified 
Aβpy3-42,…) is incubated in a native buffer, peptide aggregates are formed showing 
oligomeric species increasing in molecular weight, initially found by CD in a disordered 
(random) conformation that may transiently convert into β-sheet oligomers that assemble 
further into protofibrils, following distinct pathways according to the original monomer 
peptide. Some of these transient oligomeric aggregation states may be built by subunits in the 
hairpin conformation after conversion of intramolecular Hbonds and antiparallel β-strands 
into intermolecular Hbonds and parallel β-sheets (Hoyer et al., 2008). By engineering a double 
cysteine mutant, in which the β-hairpin is stabilized by an intramolecular disulfide bond, Aβ1-
40 and Aβ1-42 are transformed into Aβ40CC and Aβ42CC, becoming building block of toxic 
Aβ oligomers, unable to convert into amyloid fibrils (Sandbergh et al., 2010) (see figure 1). 
In figure 1, panel A,  the transient β-hairpin is first compared with the stabilized  β-hairpin by 
the two disulfide bonds in the double cystein mutants, in panel B (ThT fluorescence assay) it is 
shown that Aβ40CC is unable to transform, after incubation, in fibrils being blocked in the 
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oligomeric form (see relative TEM micrograpghs, panel C), evolution that is recovered after  
treatment of Aβ40CC with the reducing agent TCEP. The neurotoxicity of different AβCC 
aggregates was assayed by measuring their ability to induce apoptosis (level of caspase-3/7 
activity in human neuroblastoma cell line, SH-SY5Y) (Sandbergh et al., 2010). Aβ42CC 
aggregates, pooled from SEC, all induce apoptosis 24 hr after addition to the cells, but β-sheet 
oligomer fractions are considerably more toxic than low molecular weight or high molecular 
weight fractions of Aβ42CC: the β-sheet oligomers (at 1µM) resulted 50 times more potent than 
wild-type Aβ42 monomer or fibril samples (see figure 2).  
 
 
Fig. 1. Panel A. On the left, the β-hairpin conformation of A40 in complex with an Affibody 
binding protein [29]; the ALA21 and ALA30 methyls are located in close proximity on 
opposite β-strands. On the right, model of double-mutated A A21C and A30C, ACC, in 
which the β-hairpin conformation is locked by a disulfide bond. Panel B. ThT fluorescence 
assays of A40CC aggregation in the absence or presence of reducing agent (TCEP), 
compared with wild-type A40 aggregation. Panel C. TEM micrographs of β-sheet oligomers 
of A40CC (left) and of fibrils formed in presence of TCEP (right). Adapted from Figure 1 of 
reference (Sandbergh et al., 2010). 
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Fig. 2. Neutoxicity of ACC to SH-SY5Y human neuroblastoma cells. Caspase-3/7 activity 
reporting on apoptosis  was measured after 24 h of treatment with 10 µM of different  
A42CC species (blue); A42CC oligomers compared with wild-type A42 (green). Adapted 
from Figure 4 of reference (Sandbergh et al., 2010). 
 
 
Fig. 3. A aggregation via two pathways. Disordered pathway: upper; toxic β-sheet 
oligomers pathway: lower. Adapted from Figure 5 of reference (Sandbergh et al., 2010). 
In conclusion an aggregation scheme was proposed as synthesized in figure 3 (Sandbergh et 
al., 2010).  It is possible that the aggregation and kinetic plasticity of Aβ leads to different 
pathways for amyloid formation, having different impacts on AD pathogenesis (figure 3): 
one pathway involves disorganized oligomers and large non fibrillar aggregates (disordered 
less toxic pathway) and the other involves assembly in β-sheet oligomers which in turn may 
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be the building blocks of protofibrils as the penultimate intermediate before fibril seeds 
formation (toxic β-sheet oligomers pathway). Aβ42CC more readily forms β-sheet oligomers 
than Aβ40CC, probably as a result of the presence of a kinetic barrier to oligomer formation 
that can only be overcome by Aβ40CC with the aid of heating and concentration (Sandbergh 
et al., 2010). It is possible that the stronger toxicity found for Aβ42 in respect to Aβ40 reflects 
different barriers to β-sheet oligomer formation. Accordingly, the former peptide may 
follow the toxic β-sheet oligomers pathway while the latter may follow the disordered 
pathway. This concept of kinetic partitioning of Aβ into two or more aggregation pathways 
may be important in AD progress, and at the same time the choice between the different 
pathways is very subtle because morphologically very similar oligomers may show different 
cell toxicity. A demonstration of this hyperfine behaviour was finely given  by considering  
a protein model, the 91 residue N-terminal domain HypF-N of Escherichia coli (Campioni et 
al., 20 10). 
This protein, prepared in different conditions, gives two stable oligomers HypF-N-A and  
HypF-N-B of similar morphological and tintorial properties but with the first one very toxic 
and the second one almost non toxic versus human neuroblastoma cells  (SH-SY5Y), via 
MTT and Hend assays (figure 4, panel A) (Campioni et al., 2010).  
To gain insight into the structural differences of the two oligomers HypF-N-A and HypF-N-B, 
18 mutational variants of the protein were expressed, each carrying a single cysteine residue 
but located at different positions along the polypeptide chain, and labeled with a pyrene. Each 
labeled variant was allowed to aggregate separately, analysing the resulting fluorescence 
spectra with the eventual formation of pyrene excimers as a probe of the proximity (about 1 
nm) of labelled pairs. It was shown that the structural hydrophobic core of the non-toxic 
HypF-N-B oligomers is more compact and less solved exposed  (see figure 4, panel B) than the 
less tightly packed core of the toxic HypF-N-A oligomers. This demonstrates that the 
difference in cell membrane interaction and ability to cause cell dysfunction is due to the small 
differences in structural flexibility and solvent exposure of the core residues.   
Toxicity is associated with the ability of the oligomeric species to form a more pronounced 
and disruptive interaction with cells, by exposure to the solvent of the surfaces of 
hydrophobic disorganized residues and thus leading to cell death.  Thus, the protein model 
HypF-N has allowed oligomeric states, that would normally be metastable, to be trapped 
and therefore studied, with conclusions probably valid for the toxic properties of many 
oligomers in disease-related systems (Campioni et al., 2010).  
Summarizing (Campioni et al., 2010; Sandbergh et al., 2010), to form amyloid-like  structures 
is generic to polypeptide chains, but whether or not these species are pathogenic depends on 
their structural features, notably the extent to which hydrophobic residues are flexible and 
exposed on their surfaces within the environment of a living organism. Thus it seems that for 
therapeutic purposes the toxicity can be substantially reduced if the hydrophobic residues 
are incorporated to a greater extent within the interior of the oligomeric assemblies, even in 
the absence of an effective change in morphology: solvent-exposed structurally disorganized 
hydrophobic residues within small protein oligomers are at the origin of the pathogenesis of 
important human diseases.  
Nevertheless the world of Aβ assembly still is too complex to be conclusive on the related 
biological activity in neurodegenerative diseases and fundamental questions remains to be 
clarified such as: is Aβ the main proximate etiologic agent of AD?; what is the structure of 
the proximate neurotoxic Aβ assembly? (Roychaudhuri et al., 2009).  
www.intechopen.com
Structure and Toxicity of the Prefibrillar  
Aggregation States of Beta Peptides in Alzheimer’s Disease 
 
163 
 
Fig. 4. Toxicity of HypF-N aggregates. Panel A. MTT reduction assay on SH-SY5Y (gray) 
and Hend (black) cells untreated (lane 1), or treated with Aβ1-42 oligomers (lane 2), control 
IAPP oligomers (lane 3), HypF-N aggregates under condition A (lane 4) and B (lane 5) and 
native HypF-N (lane 6). Panel B. Pyrene fluorescence emission spectra: excimer ratio profiles 
of HypF-N oligomers formed under condition A (red) and B(blue).  Adapted from Figures 1 
and 3 of reference (Campioni et al., 2010). 
One of the main problems is to well characterize the structure of oligomeric states even 
when well followed: normally this is done by  TEM and AFM with a lack of resolution to 
characterize such small and dynamic structures. Recently, a new approach in AFM was 
developed at LifeAFM , Port Jefferson (NY), that yields high-resolution images and allows 
to observe the structure of the smallest MW oligomers (Mastrangelo et al., 2006). The new 
AFM methodology, at difference with conventional tapping mode AFM, is based on a single 
low-force touch of the cantilever tip, enabling a non-destructive imaging of Aβ and 
observation of the small Mw oligomers. AFM of  Aβ42 at early  incubation time, give images 
of monomers,  dimers, trimers, tetramers and other low Mw oligomers that are consistent 
with the hairpin structure, above described (Figure 5) (Mastrangelo et al., 2006).  
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Fig. 5. High resolution AFM of Aβ1-42. AFM images are interpreted as panel A: a dimer; 
panel B and C: a tetramer. In each image the diffuse area to the left of the particle is 
interpreted as the disordered N-terminal region of the Aβ1-42 monomer.  Adapted from 
Figure 4 of  reference (Mastrangelo et al., 2006). 
For the first time, images of such small oligomers were obtained, that may be interpreted as 
hairpin monomer, dimer  and tetramer (see panels d, e and f). Note that the structures 
described  above were found also in Alzheimer brains and should be present in the toxicity 
studies to clarify what structural features of the soluble oligomers are responsible of toxicity  
(Mastrangelo et al., 2006).   
3. Comparison of N-truncated and pyromodified A to full-length A 
aggregation states: Transient aggregation states and kinetics 
The N-terminal truncated and pyroglutamyl modified Aβ, as summarized in the 
introduction, accounts for the majority of the deposited peptides and of the most  toxic 
effects on neurons. Recently, it was demonstrated that, in similar initial buffer conditions 
and using three different techniques (flow cytometry, ThT fluorescence and circular 
dichroism), these N-terminal modified peptides aggregate much faster than the full-
length Aβ (D’Arrigo et al., 2009; Shilling et al., 2006). Altogether, the aggregation kinetics 
of Apy3-42 was found 20-250 by cytometry and ThT fluorescence (Shilling et al., 2006) 
and more than 30 times by CD (D’Arrigo et al., 2009) faster than that of A1-42 
respectively, depending upon the assay method. The oligomers that form β-structure 
rapidly are found to be more toxic (D’Arrigo et al., 2009; Mastrangelo et al., 2006; Shilling 
et al., 2006).   
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Fig. 6. The peptide TEM morphology after incubation in 20 mM phosphate buffer, pH 7.4 at 
37 °C. Aβ1-42: panel A, at initial incubation time; panel B, after 1 day of incubation; panel C, 
after 2 days of incubation. Apy3-42: panel D, at initial incubation time; panel E, after 1 day 
of incubation; panel F, after 2 days of incubation. The 1:1 mixture A1-42/Apy3-42: panel 
G, at initial incubation time (the arrow points to a protofibril); panel H, after 1 day 
incubation; panel I, after 2 days of incubation. Peptides concentrations: 50 μM. Adapted 
from Figures 6 and 7 of  reference (D’Arrigo et al., 2009). 
In addition  the aggregation pathway of the two A leads to more toxic dynamic oligomeric 
states for Apy3-42 and to fibril formation for  A1-42, see for instance (D’Arrigo et al., 2009) 
and  (He & Barrow, 1999), while when the two are mixed (e.g. in a 1:1 ratio) Apy3-42 has an 
inhibitory effect on the fibrillogenesis of A1-42, favouring  prefibrillar aggregation states, 
that are more toxic for the cells (see Figure 6) (D’Arrigo et al., 2009).  
These experiments confirm the strong role of Apy3-42 on the progression of Alzheimer 
pathogenesis  (D’Arrigo et al., 2009; Jan et al., 2008). 
The Aβ peptides display regions that are more affected by environmental conditions which 
may be responsible for conformational transitions and for different aggregation states and 
kinetics towards fibrillization (D’Arrigo et al., 2009). This has been confirmed experimentally, 
especially by NMR (Danielsson et al., 2006; Hou et al., 2004; Tomaselli et al., 2006),  and it can 
be well illustrated by a simple model using the basic properties of the 20 aminoacids. In Figure 
7 a model of the two Aβ peptides, A1-42 and Apy3-42, is reported  (D’Arrigo et al., 2009), as 
a string of pearls where each pearl represents one amino acid. Each aminoacid has one of 5 
colours, each colour corresponding to the 5 generic standard classification of the 20 
aminoacids: red, negatively charged residue; blue, positively charged residue; yellow, polar 
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residue; black, hydrophobic residue; white, Gly residue. The C-terminals of the three peptides 
and the N-terminal of Aβ1-42 are represented by red and blue squares respectively. 
 
 
Fig. 7. Five colors representation pearl chain model of Aβ1-42 and  Aβpy3-42 8 (panel A) . 
Red pearl: negatively charged residue; Blue pearl: positively charged residue; Yellow 
pearl: polar residue; Black pearl: hydrophobic residue; White pearl: Gly residue. The C-
terminals of the two peptides and the N-terminal of Aβ1-42 are represented by red and 
blue squares respectively. Conformation of Aβ1-40, according to NMR analysis (panel B) 
of ref. [32]. The proposed β-hairpin structure of toxic oligomers (panel C), see ref. [32]. 
Adapted from Figure 9 of reference (D’Arrigo et al., 2009) and Figure 6 of reference 
(Danielsson et al., 2006). 
The central hydrophobic region 16-24 is crucial for the β-sheet forming oligomerization and 
subsequent fibril formation (Danielsson et al., 2006) and is well identified in the 5-colour 
representation. On the contrary the N-terminal region 1-16 has a large propensity, 
demonstrated by NMR, to be in an extended (especially at low temperature, where, 
accordingly, Aβ is found more soluble) PII-helix which is retained going from apolar to 
polar environments, or binding metal ions, or partially retained raising the temperature  
(Danielsson et al., 2006; Tomaselli et al., 2006). Again the NMR findings have a rough 
correspondence with the 1-16 sequence in the 5 colour representation of Aβ1-42, even 
though the correlation is less strong. Reducing or removing the helix propensity of the N-
terminal region may favor a faster and different aggregation. One way to realize this 
enhancement of the aggregation process is just to destabilize the N-terminal region of Aβ1-
42 by truncating the first two residues and by pyroglutamyl termination to Aβpy3-42. Going 
from Aβ1-42 to Aβpy3-42 the N-terminal portion of Aβ suffers important and indicative 
changes: the negative charges decrease from 7 to 5, the positive charges from 4 to 3, globally 
the terminal chain loosing 3 charges, while the hydrophobic residues decrease only by one 
in favour of an equal increase in polar residues. On this basis one may infer  (D’Arrigo et al., 
2009) that the helix propensity of the N-terminal is strongly reduced and the peptide, in 
which the central hydrophobic part did not make any change, is now more prone to the  
conformational state and to aggregation, as observed by CD  (D’Arrigo et al., 2009; He & 
Barrow, 1999).  
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Different Aβ peptides, full-length and truncated and modified, do have different attitude to 
develop the cross-β structure conformation with big consequences not only on fibrillization but 
also on the aggregation kinetics and on the formation of different prefibrillar aggregation states.  
So these N-terminal truncations and pyroglutamil modifications of Aβ1-42 have the 
consequences of accelerating the initial aggregation kinetics, directing it towards faster 
oligomerization. In addition, the py-Glu residue prevents degradation of the peptide by 
aminopeptidase  (Shilling et al., 2004, 2006) and at the same time, as demonstrated by TEM, 
Aβpy3-42 inhibits the great propensity of the full-length peptide to aggregate in fibrils, 
favouring and stabilizing pre-fibrillar aggregation states that may be very toxic for the cells 
and for the progression of Alzheimer pathogenesis (D’Arrigo et al., 2009).  
4. Inhibition of the most toxic prefibrillar aggregates as a new therapeutic 
strategy against Alzheimer pathogenesis 
From sections 2 and 3 it comes out that a possible new therapeutic strategy against AD  may be 
based on the inhibition of the highest toxic prefibrillar aggregates (Ono et al., 2009). As we 
have seen before, this means that attention should be directed to reduce the Aβ prefibrillar 
aggregations particularly of those more stable components which are organized in such a way 
to be greatly toxic to neuron cells.  This logic suggests to target ordered oligomers and small 
ordered aggregates, destabilizing them in favour of disorder states. This is something that 
applies to all the forms of Aβ peptides, but it should be even of more importance to target 
special peptides such as the N-terminal truncated and pyroglutamyl modified peptides like 
Aβpy3-42. This strategy was strongly pursued by Demuth’s group. In a remarkable 2008 paper 
on Nature Medicine (Shilling et al., 2008), Demuth and coll. Indicate, by experiments in vivo 
and in vitro, that inhibition of the level of glutaminyl cyclase (QC) in mammalian brains, 
where it is widely distributed, attenuates pyroglutamate Aβ and AD pathology. 
To assess whether QC expression can be correlated with generation of Aβpy3-42 in AD, QC 
mRNA and protein concentrations in human neocortical brain samples post mortem were 
analysed (figure 8A). It was found that QC mRNA and protein were upregulated in samples 
from AD individuals, compared with samples from normal aging individuals; significantly 
larger concentrations of Aβpy3-42 were detected by ELISA analysis in the former individuals 
relative to the latter (figure 8B). This supports the role of QC in the generation of Aβpy3-42. In 
contrast high total Aβx-42 concentrations in aged controls were found (figure 8B). 
The protein APP and QC were co-expressed in HEK293 cells to study the correlations 
between QC expression and Aβpy3-42 generation (Shilling et al., 2008). When the first potent 
inhibitor for human QC, PDB150 (Buchholz et al., 2006), was added, the Aβpy3-42 formation 
was suppressed the most the highest the inhibitor dose, while the other non pyromodified 
peptides were not affected (figure 8C). This demonstrates the specific effect of the inhibitor 
on QC catalysis (figure 8C and 8D). 
Subsequently PBD150 was orally applied to 4-month-old female Tg2576 mice for 6 months 
to study effects of QC inhibition on the Aβpy3-42 and on non pyromodified peptides in the 
insoluble Aβ pool (Shilling et al., 2008). Aβpy3-42 decreased by 23% and 65% according to 
the PBD150 dose as well as the non pyromodified peptides. Two are therefore the 
indications in vivo: Aβpy3-42 generation is mediated by QC and there is a correlation 
between Aβpy3-42 aggregation and  total Aβ aggregation.  
These interesting conlusions were confirmed by other experiments on the effects of QC 
inhibition on Tg256 mice and on TASD-41 mice (Shilling et al., 2008).  
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It seems to us that the conclusions of the authors of the above paper (Shilling et al., 2008), 
that prevention of pyroglutamate Aβ at the N-terminus by QC inhibition represents a new 
therapeutic strategy for alleviating amyloidoses caused by the seeding of amyloidogenic 
peptides, was well substantiated. This may represent an important step to get a first 
molecular strategy in AD therapy. 
 
 
Fig. 8. Glutamynil cyclase (QC) expression and pyroglutamate-modified N-terminally 
truncated Aβ: prevention of  Aβpy formation by glutamynil cyclase inhibition in vitro and in 
vivo. Panel A: quantitative analysis of QC transcript levels. Total RNA from human 
neocortical brain samples was isolated from aged controls and individuals with AD (the 
Roman numerals in ADI, ADII, ADV-VI refer to Braak stages). Panel B: Quantification of 
Aβpy3-42 and Aβ1-42 concentrations from the samples of Panel A by ELISA analysis. Panel 
C: quantification of Aβ concentrations in conditioned media of HEK293 cells, which were 
transiently transfected with an APPsw/l variant and human QC. PBD150 lc (low 
concentration) = 0.1µM; (high concentration) = 1 µM. Panel D: quantification of Aβ 
concentrations in the brains of 10-month old  Tg2576 control mice and of age-matched 
littermates treated for 6 months with PBD150 at a concentration of 2.4 mg per g (PBD150lc) 
or 7.2 mg per g (PBD150lc) of food pellets. Only female mice were enrolled in the study.  
Adapted from Figure 1 of (Shilling et al., 2008).  
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5. Conclusion 
We firstly introduced the prefibrillar aggregation states that are thought to be responsible 
of the progress of Alzheimer’s pathogenesis, and then discussed the possible peptide 
conformation and assembly organization of them. These features has been correlated with 
their peptide content, particularly full-length Aβ1-42 and N-truncated and modified 
Aβpy3-42,  their structure, kinetics and cell toxicity. We have reviewed the elements of a 
new therapeutic strategy generically based on opposing conformational diseases taking 
into account properly of the conformational and structural organization of most toxic 
oligomeric aggregates. One of the most toxic oligomeric aggregates is formed by Aβpy3-
42: the new therapeutic strategy may be the prevention of pyroglutamyl termination by 
finding a well tolerated inhibitor of glutamynil cyclase, which is responsible of the 
catalysis in vivo of this termination. More difficult is to find conformational inhibitors of 
the more extended variety of amyloid peptides participating to the formation of the most 
toxic oligomeric aggregation states. If some steps in the new therapeutic strategy have 
been done, more work is required to determine more extensively the conformation and 
structure of the possible oligomeric states and their interaction with neuronal cells to 
clarify the mechanism of  toxicity. 
Finally, we have not treated here this topic, but evidence exists that metals are involved as 
well,  in the pathogenesis of AD but the mechanism and role, although important it remains 
unclear.  
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